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Abstract
Early onset torsion dystonia (EOTD) is a rare movement disorder characterized by involuntary,
repetitive, sustained muscle contractions or postures involving one or more sites of the body. A
US study estimated the prevalence at approximately 1 in 30,000. The estimated prevalence in the
general population of Europe seems to be lower, ranging from 1 in 330,000 to 1 in 200,000,
although precise numbers are currently not available. The estimated prevalence in the Ashkenazi
Jewish population is approximately five to ten times higher, due to a founder mutation. Symptoms
of EOTD typically develop first in an arm or leg in middle to late childhood and progress in
approximately 30% of patients to other body regions (generalized dystonia) within about five years.
Distribution and severity of symptoms vary widely between affected individuals. The majority of
cases from various ethnic groups are caused by an autosomal dominantly inherited deletion of 3 bp
(GAG) in the DYT1 gene on chromosome 9q34. This gene encodes a protein named torsinA, which
is presumed to act as a chaperone protein associated with the endoplasmic reticulum and the
nuclear envelope. It may interact with the dopamine transporter and participate in intracellular
trafficking, although its precise function within the cell remains to be determined. Molecular genetic
diagnostic and genetic counseling is recommended for individuals with age of onset below 26 years,
and may also be considered in those with onset after 26 years having a relative with typical early
onset dystonia. Treatment options include botulinum toxin injections for focal symptoms,
pharmacological therapy such as anticholinergics (most commonly trihexiphenydil) for generalized
dystonia and surgical approaches such as deep brain stimulation of the internal globus pallidus or
intrathecal baclofen application in severe cases. All patients have normal cognitive function, and
despite a high rate of generalization of dystonia, 75% of those patients are able to maintain
ambulation and independence, and therefore a comparatively good quality of life, with modern
treatment modalities.
Disease name and synonyms




Early onset torsion dystonia (EOTD) is characterized by
involuntary, repetitive, sustained muscle contractions or
postures, typically of the limbs, which may spread to
other body parts, in the absence of other neurological
abnormalities. It is inherited in an autosomal dominant
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fashion with a penetrance of only 30–40% [1], suggesting
that various genetic and/or environmental factors contrib-
ute to development of the disease. The majority of cases
are caused by a deletion of 3 bp (GAG) in the DYT1 gene
on chromosome 9q34.
The term "Dystonia" in general refers to a large diverse
group of movement disorders involving involuntary mus-
cle contractions or postures. It may be classified in three
ways:
(1) clinically, i.e. according to age at onset or distribution
of affected body regions;
(2) etiologically, i.e. into primary, secondary, dystonia-
plus or heredodegenerative;
(3) genetically, with 15 loci described to date.
Diagnostic criteria
The following diagnostic criteria have been established for
EOTD [1-3]:
Definite dystonia
Characteristic overt twisting or directional movements
and postures that are consistently present.
Probable dystonia
Postures or movements suggestive of dystonia that are
insufficient in intensity or consistency to merit classifica-
tion as definite (e.g. excessively tense and labored writing
with minimal posturing, flurries of blinking but no epi-
sodes of sustained closure, etc.).
Possible dystonia
Muscle contractions not considered abnormal but
remotely suggestive of dystonia (e.g. unusual hand grip
with mild excess hand tension but normal flowing hand-
writing, increased blinking with no flurries or sustained
contractions, etc.).
Only the category of "definite dystonia" was shown to be
100% specific in DYT1 families [3], suggesting that only
those patients with definite signs of dystonia should be
considered affected in genetic research studies.
Epidemiology
EOTD is a rare disease, with an estimated prevalence of
3.4:100,000 and annual incidence of 0.2:100,000 in
Rochester, Minnesota [4]. The prevalence in the
Ashkenazi Jewish (AJ) population is estimated to be five
to ten times higher [5], due to a founder mutation which
appears to have arisen approximately 350 years ago in
Byelorussia/Lithuania [6]. The frequency of the DYT1
GAG deletion in the AJ population is high, between
1:2000 and 1:6000. In contrast, the prevalence in the gen-
eral population of Europe seems to be lower. Estimates
range from 0.3 to 0.5:100,000 although precise numbers
are currently not available.
Clinical description
EOTD is characterized by involuntary, repetitive, sus-
tained muscle contractions or postures involving one or
more sites of the body. Typically, symptoms develop first
in an arm or leg in middle to late childhood (mean age of
onset: 12.5 years) [7] and progress in approximately 30%
of patients to other body regions (generalized dystonia)
within about five years [8]. "Torsion" refers to the twisting
nature of body movements observed in EOTD, often
affecting the trunk. Patients may be severely physically
incapacitated, but are normal intellectually and show no
other neurological symptoms. Distribution and severity
of symptoms vary widely between affected individuals,
ranging from mild focal dystonia, e.g. writer's cramp [9] to
severe generalized dystonia, even within families [10].
Earlier age of onset and onset in the legs predicts a more
severe clinical course, i.e. development of generalized dys-
tonia [11,12].
The DYT1 GAG deletion is responsible for the majority of
typical early onset dystonia cases of diverse ethnic origins,
whether inherited or caused by a de novo mutation,
whereas only a small minority of patients with atypical,
e.g.  focal dystonia, harbor this mutation [7,13-18]. If
mutant gene carriers pass the age of approximately 28
years without developing symptoms, they usually escape
the disease for life.
Etiology
Neuropathologically, EOTD is characterized by a lack of
neurodegeneration, suggesting that neuronal dysfunction,
rather than loss of neurons, underlies disease symptoms.
However, cell bodies of dopaminergic neurons appear to
be enlarged in brains from dystonia patients [19]. In the
brains of four DYT1 patients, perinuclear inclusion bodies
in specific brainstem areas (pedunculopontine nucleus,
periaqueductal gray) have been reported [20]. These find-
ings have been recapitulated in two different DYT1 animal
models, both in transgenic mice overexpressing human
mutant ∆E-torsinA [21] and in male DYT1 ∆GAG knock-
in mice [22]. Despite the low penetrance of only 30–40%
for clinical symptoms, functional imaging studies found
metabolic hyperactivity in the lentiform nuclei, cerebel-
lum and supplemental motor areas, and impaired
sequence learning in both manifesting and non-manifest-
ing carriers of the DYT1  GAG deletion, indicating that
penetrance of the GAG deletion is greater than that
assumed based on clinical grounds [23,24]. In addition, a
recent study found that striatal D2 receptor binding was
reduced in non-manifesting carriers of the DYT1  GAGOrphanet Journal of Rare Diseases 2006, 1:48 http://www.OJRD.com/content/1/1/48
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deletion. This reduction may be a trait feature of DYT1
dystonia, with other factors being necessary for manifesta-
tion of the signs and symptoms. Alternatively, clinical
penetrance may be linked to the extent of the decrease in
striatal D2 receptor binding [25].
The DYT1 gene encodes the torsinA protein. TorsinA is an
endoplasmic reticulum/nuclear envelope (NE) ATP-
dependent chaperone protein [26,27] involved in intrac-
ellular trafficking [28]. Mutant ∆E-torsinA relocalizes to
the NE [27,29,30], and postmigratory neurons from both
torsinA null and homozygous mutant knock-in mice
develop membrane abnormalities of the NE [31]. In addi-
tion, recent studies in mammalian cell lines have shown
that overexpression of wild-type torsinA appears to regu-
late the intracellular trafficking of the dopamine trans-
porter, whereas overexpression of mutant ∆EtorsinA had
no effect. These results establish a potential link between
torsinA and the dopaminergic system [59].
Several lines of evidence suggest that the disease is caused
by a dysfunction of the basal ganglia: (1) Although
torsinA is ubiquitously expressed, expression levels within
the human brain are highest within dopaminergic neu-
rons of the substantia nigra [32]; (2) Striatial [18F]dopa
uptake is mildly reduced in manifesting DYT1 GAG dele-
tion carriers [33]; (3) An increase in the ratio of dopamine
metabolites to dopamine was found in the postmortem
striatum of DYT1 dystonia brains as compared to controls
[34]; (4) A phenotypically similar form of inherited dys-
tonia, dopa-responsive dystonia (DRD), is caused by
insufficient synthesis of dopamine [35,36], and sympto-
matic dystonia frequently affects patients with acquired
lesions of the basal ganglia (e.g. stroke) [37,38].
Diagnostic methods
Molecular genetic diagnostic in conjunction with genetic
counseling is recommended for individuals with age of
onset below 26 years, and may also be considered in those
with onset after 26 years having a relative with typical
early onset dystonia [7].
Differential diagnosis
Differential diagnosis includes other forms of primary
dystonia and disorders in which dystonia is one of several
neurological conditions present. The second large and
diverse group includes the dystonia-plus syndromes, the
heredodegenerative dystonias, the secondary ("sympto-
matic") dystonias, other dystonia-like conditions, and
early-onset parkinsonism.
Other forms of primary dystonia (DYT2, 4, 6, 7 and 13)
The phenotype of DYT2 dystonia, an autosomal recessive
form of dystonia, resembles early onset torsion dystonia
(DYT1) in three of the four families reported to date (early
onset of symptoms, frequently in the feet, followed by
rapid generalization) [39,40]. However, there is a debate
as to whether the mode of inheritance in these families is
actually autosomal recessive or autosomal dominant with
reduced penetrance [41].
The DYT4 locus has been assigned to an Australian family
with predominant whispering dysphonia and additional
variable dystonic symptoms [42,43], clearly different phe-
notypically from classical DYT1 dystonia.
DYT6 refers to another autosomal dominant form of dys-
tonia of mixed-type described in two German-Mennonite
families [44]. In contrast to DYT1 dystonia, the average
age at onset in these families was higher (18.6 years, range
5–38), and in many patients dystonic symptoms were pre-
dominantly cranio-cervical, with progression to general-
ized dystonia in only a few cases.
DYT7  refers to a locus for adult-onset focal, predomi-
nantly cervical dystonia mapped in a German family [45].
The DYT13 locus has been mapped in a non-Jewish Italian
family [46] with mostly segmental dystonia with promi-
nent cranio-cervical and arm involvement, more closely
resembling the DYT6 than the DYT1 phenotype.
Dystonia-plus (DYT5, DYT11 and DYT12)
Dystonia-plus refers to conditions in which dystonia is
one of only two neurological abnormalities present, the
other usually being either parkinsonism or myoclonus.
This group includes Dopa-Responsive Dystonia (DRD,
DYT5), Myoclonus-Dystonia (DYT11) and Rapid Onset
Dystonia-Parkinsonism (DYT12).
Heredodegenerative dystonias (DYT3 and others)
In heredodegenerative dystonias, dystonia is part of a
more widespread neurodegenerative syndrome, often
with known inheritance, and may or may not be a prom-
inent feature. This large group includes X-linked Dysto-
nia-Parkinsonism ("Lubag", DYT3), Idiopathic
Parkinson's Disease (IPD), Multiple System Atrophy
(MSA), Progressive Supranuclear Palsy (PSP), Haller-
vorden-Spatz Disease, Wilson's disease, Rett syndrome,
Neuroacanthocytosis, and many others.
Secondary dystonia
Secondary (symptomatic) dystonias are caused by envi-
ronmental insults such as stroke, tumors, infections, drugs
and toxins or by metabolic disorders (e.g. homocysteinu-
ria, metachromatic leukodystrophy, Lesch-Nyhan syn-
drome, and others).Orphanet Journal of Rare Diseases 2006, 1:48 http://www.OJRD.com/content/1/1/48
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Other dystonia-like conditions (DYT8, DYT9, and DYT10)
This group includes conditions mimicking symptoms of
dystonia (e.g. psychogenic dystonia or pseudodystonia)
and paroxysmal disorders, such as paroxysmal non-
kinesigenic dystonia (PNKD, DYT8), paroxysmal chore-
oathetosis with episodic ataxia and spasticity (DYT9), par-
oxysmal kinesigenic dystonia (PDK, DYT10), and others.
Early onset parkinsonism
A considerable proportion of early onset Parkinson's dis-
ease, with onset of symptoms before 40 years of age, is
caused by mutations in the Parkin  gene [47] and fre-
quently presents with dystonia, especially in the lower
limbs [48]. Thus, this condition should be considered in
the differential diagnosis of EOTD.
Genetic counseling
Based on a systematic genetic and clinical analysis of 267
individuals with primary torsion dystonia, including
Ashkenazi Jewish and non-Jewish patients, diagnostic
DYT1 testing in conjunction with genetic counseling is
recommended for individuals with an age of onset below
26 years, and may also be considered in those with onset
after 26 years having a relative with typical EOTD [7].
Genetic counseling should take into account that DYT1
dystonia is inherited in an autosomal dominant manner
with a low penetrance of 30–40% and great clinical varia-
bility. Few cases of de novo mutations have been reported
[49,50]. Asymptomatic adult relatives should be informed
before testing that onset of DYT1 dystonia after age 26 is
very unlikely, and that, if it occurs, symptoms are usually
mild and unlikely to progress [7]. Testing of asympto-
matic at-risk individuals during childhood is not recom-
mended. In addition to prenatal testing through chorionic
villus sampling, preimplantation genetic diagnosis has
recently been reported [51].
Management including treatment
Drug therapy
As DRD (DYT5) is phenotypically very similar to EOTD,
but its symptoms, in contrast to EOTD, typically respond
very well to dopaminergic therapy, it is recommended
that every patient with early onset focal dystonia (onset
below 26 years) be given a trial of L-Dopa/decarboxylase
inhibitor, starting with 1 mg/kg per day of levodopa and
slowly increasing until complete benefit is achieved or
dose-limiting side effects appear. Most DRD patients
respond well to 4–5 mg/kg per day [52].
In general, drug therapy in EOTD is not very effective.
Anticholinergics, especially in a high dosage (e.g. trihex-
iphenydil up to 30–60 mg/day), are the only substance
class for which controlled studies are available [53]. Dos-
age should be increased very slowly to prevent side effects
such as cognitive or memory deficits, which are frequently
dose-limiting, although children can generally tolerate
much higher doses than adults. Other substances, which
may or may not be effective, include baclofen, benzodi-
azepines such as diazepam or clonazepam, pimozid or
tetrabenazin. In severe cases of segmental or generalized
dystonia, especially of the lower body and trunk, intrath-
ecal baclofen administration may be considered [54].
Botulinum toxin injections
Independent of genetic background, local botulinum
toxin injections directly into affected muscles now repre-
sent the first line treatment of focal dystonias (reviewed in
[55]). Therefore, botulinum toxin injections by trained
movement disorder specialists may be a useful therapy for
selected muscle groups in EOTD, such as neck muscles for
torticollis, facial muscles for blepharospasm or hand/arm
muscles for writer's cramp. If successful, the injections
need to be repeated on a regular basis (usually every 3–6
months).
Surgical approaches
Due to technical advances in recent years, interest in func-
tional surgical approaches in dystonia has been renewed,
in particular deep brain stimulation (DBS) of the globus
pallidus and pallidotomy (reviewed in [56]). Although
experience with this approach is still limited, preliminary
results in patients with primary generalized dystonia,
especially DYT1 GAG deletion carriers, are very promising
[57]. Therefore, DBS may be helpful in selected EOTD
patients with severe generalized dystonia.
Prognosis
Only few studies on the natural history of EOTD in genet-
ically confirmed patients have been conducted. In one
report following the clinical course of 33 patients from
Israel [58], 63.6% had progressed into generalized dysto-
nia after a mean of 15.5 +/- 13.8 years of symptoms, 15%
were wheelchair-bound and 9% were using walking aids.
All patients had normal cognitive function. Despite the
high rate of generalization, 75% of those patients were
able to maintain ambulation and independence, and
therefore a comparatively good quality of life, with mod-
ern treatments combining drugs, botulinum toxin and
functional neurosurgery.
Unresolved questions
Very little is known yet about the normal cellular function
of the torsinA protein. Further studies are required to
address how mutant torsinA causes neuronal dysfunction,
and how this mutation leads to a dominantly inherited
disease with a markedly low penetrance and a very selec-
tive neurological phenotype. Since the age of onset is asso-
ciated with a period of motor learning and high synaptic
plasticity, a possible role of torsinA in coordinated neuro-
nal development merits further investigation. In addition,Orphanet Journal of Rare Diseases 2006, 1:48 http://www.OJRD.com/content/1/1/48
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further evidence for or against direct involvement of the
dopaminergic system in EOTD is warranted.
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